Norovirus infection cost-effectiveness of therapy: Difference between revisions
m (Changes made per Mahshid's request) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
== References == | ==Overview== | ||
The cost of Norovirus prevention and therapy will save long lasting burden of the infection in the susceptible population. | |||
==Cost effectiveness of Therapy== | |||
Noroviruses are a well-known major cause of [[acute gastroenteritis]] in the developed world, yet our ability to prevent and control infection is limited. Recent studies have demonstrated that a typical infection may present itself as acute in the normal population, while long-lasting (i.e. years) in the [[immunocompromised host]]. These patents and those regularly exposed to infectious material, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy. | |||
Considering the the [[Socio-economic status|socio-economic]] impact of norovirus infection, the case for the event of antiviral approaches and effective vaccines is powerful. There have been vaccines proven efficient against noroviruses in cell culture and a minimum of one in a the mouse model, non of which have made it through to clinical use for the [[treatment]] or [[prevention]] of norovirus infection. Since the therapy is to target intestinal pathogens, there's a big problem related to the stability of the vaccine in this rather harsh environment as well as its delivery to the replication site. Subsequently, there are variety of great obstacles to overcome for the utilization of those inhibitors in an exceedingly clinical setting.<ref name="pmid24199805">{{cite journal| author=Arias A, Emmott E, Vashist S, Goodfellow I| title=Progress towards the prevention and treatment of norovirus infections. | journal=Future Microbiol | year= 2013 | volume= 8 | issue= 11 | pages= 1475-87 | pmid=24199805 | doi=10.2217/fmb.13.109 | pmc=3904215 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24199805 }} </ref> | |||
==References== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 15:03, 29 January 2021
|
Norovirus infection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Norovirus infection cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Norovirus infection cost-effectiveness of therapy |
|
Norovirus infection cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Norovirus infection cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
The cost of Norovirus prevention and therapy will save long lasting burden of the infection in the susceptible population.
Cost effectiveness of Therapy
Noroviruses are a well-known major cause of acute gastroenteritis in the developed world, yet our ability to prevent and control infection is limited. Recent studies have demonstrated that a typical infection may present itself as acute in the normal population, while long-lasting (i.e. years) in the immunocompromised host. These patents and those regularly exposed to infectious material, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy. Considering the the socio-economic impact of norovirus infection, the case for the event of antiviral approaches and effective vaccines is powerful. There have been vaccines proven efficient against noroviruses in cell culture and a minimum of one in a the mouse model, non of which have made it through to clinical use for the treatment or prevention of norovirus infection. Since the therapy is to target intestinal pathogens, there's a big problem related to the stability of the vaccine in this rather harsh environment as well as its delivery to the replication site. Subsequently, there are variety of great obstacles to overcome for the utilization of those inhibitors in an exceedingly clinical setting.[1]
References
- ↑ Arias A, Emmott E, Vashist S, Goodfellow I (2013). "Progress towards the prevention and treatment of norovirus infections". Future Microbiol. 8 (11): 1475–87. doi:10.2217/fmb.13.109. PMC 3904215. PMID 24199805.